Neurofilament, Light Polypeptide Proteins (NEFL)

Neurofilaments are type IV intermediate filament heteropolymers composed of light, medium, and heavy chains. Additionally we are shipping Neurofilament, Light Polypeptide Antibodies (270) and Neurofilament, Light Polypeptide Kits (24) and many more products for this protein.

list all proteins Gene Name GeneID UniProt
NEFL 18039 P08551
NEFL 4747 P07196
NEFL 83613 P19527
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top Neurofilament, Light Polypeptide Proteins at antibodies-online.com

Showing 7 out of 7 products:

Catalog No. Origin Source Conjugate Images Quantity Delivery Price Details
Escherichia coli (E. coli) Human His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg 30 to 35 Days
$5,370.21
Details
HEK-293 Cells Human Myc-DYKDDDDK Tag Validation with Western Blot 20 μg 11 Days
$888.80
Details
Yeast Mouse His tag 100 μg 8 to 11 Days
$523.60
Details
Wheat germ Human GST tag 2 μg 11 to 12 Days
$230.67
Details
Yeast Rat His tag   1 mg 60 to 71 Days
$3,545.67
Details
Escherichia coli (E. coli) Mouse His tag 100 μg 15 to 18 Days
$560.00
Details
Escherichia coli (E. coli) Human Un-conjugated 100 μg 15 to 18 Days
$608.00
Details

NEFL Proteins by Origin and Source

Origin Expressed in Conjugate
Mouse (Murine) ,

Human , ,
, ,
Rat (Rattus)

More Proteins for Neurofilament, Light Polypeptide (NEFL) Interaction Partners

Mouse (Murine) Neurofilament, Light Polypeptide (NEFL) interaction partners

  1. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice

  2. NFL deficits cause an N-methyl-D-aspartic acid receptor hypofunction phenotype including abnormal hippocampal function, as seen in schizophrenia. NFL-/- deletion in mice reduces dendritic spines and GluN1 protein levels, elevates ubiquitin-dependent turnover of GluN1 and hippocampal glutamate measured by MRS, and depresses hippocampal long-term potentiation.

  3. Study found that NFL protein levels are at least doubled in pmn mutant motoneurons and that NFL depletion rescues defective axon growth in cultured motoneurons and prolongs survival of pmn mutant mice. This effect was found both in Nefl+/-;pmn motoneurons in which elevated NF expression was brought back to wild-type control levels and in Nefl-/-;pmn motoneurons in which axonal neurofilament was completely lost.

  4. It may have a role in protecting neurites from dystrophy and in regulating cellular pathways related to the generation of Ab plaques.

  5. Nefl(N98S/+) mice had a noticeable tremor, and most animals showed a hindlimb clasping similar to human Charcot-Marie-Tooth Type 2E phenotype.

  6. Mice lacking NF-Lr ecapitulated the delayed synapse elimination phenotype observed in micelacking Nfasc155.

  7. The finding of this study suggested that a lack of NFL protein alters the expression of cytoskeletal proteins and disrupts other NF subunits, causing intracellular aggregation but not gross structural changes in cortical neurons or cytoarchitecture.

  8. Neurofilament light chain (NFL) and neuronal intermediate filament protein alpha-internexin accumulate in axon swellings in the spinal white matter in a superoxide dismutase (SOD)-1 mouse model.

  9. Data suggest that tetrahydropapaveroline (an endogenous catechol) causes oxidative stress resulting in astrocyte/neuronal cell death via generation of reactive oxygen species and modification/aggregation of NF-L (as in neurodegenerative diseases).

  10. Data show that mitochondria essentially stopped moving in neurons expressing neurofilament protein (NFL) mutants, probably a consequence of cytoskeletal disruption.

  11. Myo Va interactions with intermediate filament proteins may serve similar roles in organizing organelle topography in different cell types.

  12. NEFL transgenic mice exhibited extended duration of the hindlimb clasping response and gait anomalies, as well as sensorimotor deficits in stationary beam and suspended bar tests

  13. Neuropathic effects of overexpressing NF-L can occur at the level of transgene RNA and are mediated by sequences in the NF-L 3' UTR

  14. nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum

  15. The 3' untranslated region of light neurofilament (NF-L) transcript enhances the reactivity of its own translated product and leads to loss of solubility and aggregation of NF-L protein and to coaggregation of mutant superoxide dismutase 1 (SOD1) protein

  16. copper-mediated NF-L modification may be closely related to oxidative reactions which play a critical role in neurodegenerative diseases

  17. We observed three overlapping phases in NF-L transgenic mice, including transient aggregate formation, reactive microgliosis, and progressive motor neuron loss.

  18. p190RhoGEF is involved in aggregation of NF-L protein and support a working hypothesis that aggregation of p190RhoGEF and NF-L is an upstream event triggering neurotoxicity in motor neuron disease.

  19. Mouse lactotrophs, gonadotrophs, thyrotrophs and somatotrophs express NF68 in a sexually dimorphic manner. Mouse pituitary cells from the proopiomelanocortin lineage nearly completely lack NF68 immunoreactivity.

  20. Alpha-internexin coassembles with all 3 neurofilament proteins into a single network of filaments in quadruple-transfected cells.

Human Neurofilament, Light Polypeptide (NEFL) interaction partners

  1. mutant huntingtin (mHTT) and neurofilament light (NfL) protein concentrations in cerebrospinal fluid (CSF) and blood in parallel with clinical evaluation and magnetic resonance imaging in premanifest and manifest Huntington disease mutation carriers, were examined.

  2. Study showed that Increased neurofilament light (NFL) correlated with multiple brain DTI metrics. An NFL x diagnosis interaction on white matter microstructure was detected, with associations strongest among mild cognitive impairment.

  3. Serum neurofilament light chain is a relevant and promising biomarker in progressive supranuclear palsy for disease severity.

  4. Recently, NfL was found to be increased in the blood and CSF of patients with amyotrophic lateral sclerosis and Creutzfeldt-Jakob disease, suggesting NfL as a biomarker in rapidly progressive neurodegenerative diseases

  5. The sNfL concentrations were elevated in line with stroke severity, assessed either clinically or from subsequent CT imaging.

  6. Cerebrospinal fluid lactate and neurofilament light (NF-L) were significantly increased in patients with mitochondrial encephalopathy compared to controls. Elevated cerebrospinal fluid NF-L was associated with abnormal brain MRI and poorer survival.

  7. The significantly raised plasma NfL concentration in patients with CMT and its correlation with disease severity suggest that plasma NfL holds promise as a biomarker of disease activity

  8. GWAS found the associations of two single nucleotide polymorphisms (rs7943454 and rs640476) with plasma NFL at suggestive levels

  9. NfL dynamics in serum predict disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer's disease.

  10. NF-L may be involved in severity of neuronal injury following traumatic brain injury

  11. CSF neurofilament light chain protein is an accurate marker for distinguishing Alzheimer's disease patients from healthy controls.

  12. Cerebrospinal fluid neurofilament protein light is a useful tool for determining disease intensity in frontotemporal dementia and motor neuron disease patients.

  13. Our results suggest that plasma NFL levels may not be a useful biomarker for the diagnosis of prodromal and dementia stages of AD.

  14. In this Chinese Han population a novel Charcot-Marie-Tooth disease-associated gene mutations of NEFL (c.280C>T) was discovered.

  15. We conclude that low BDNF and high LCN2 and NF-L levels are associated with Multiple Sclerosis (MS) pathogenesis, and high IGFBP1level is a biomarker for female MS only, suggesting different MS progression pathways between the sexes. LCN2 is a candidate predictor of response to natalizumab treatment, and NF-L is a candidate predictor of clinically isolated syndrome's (CIS) conversion into MS.

  16. This study showed tat Serum NfL concentration is increased in familial Alzheimer disease prior to symptom onset and correlates with measures of disease stage and severity. Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration.

  17. Results show that both alphaS and NFL can be phosphorylated by CKII, PLK2 and PLK3, but Ser129 in alphaS is a preferential site for PLK2 and PLK3, demonstrating higher phosphorylation efficiency. Comparatively, CKII preferentially phosphorylates Ser473 in NFL and this site can be phosphorylated by PLK1, 2 and 3, but these enzymes prefer to modify other sites within NFL.

  18. Results provide evidence that in particular pNfH can be used as a good diagnostic biomarker of ALS at the diagnostic stage. Moreover, results indicate that NfL may be useful in monitoring disease progression in a subset of patients.

  19. fL is a weak independent risk factor in clinically isolated syndromes for conversion to multiple sclerosis. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes.

  20. Level of neurofilament heavy chain and light chains were significantly elevated in the cerebrospinal fluid of Amyotrophic Lateral Sclerosis (ALS) patients compared to healthy controls/controls without parenchymal central nervous system involvement and ALS mimic disease patients.

Neurofilament, Light Polypeptide (NEFL) Protein Profile

Protein Summary

Neurofilaments are type IV intermediate filament heteropolymers composed of light, medium, and heavy chains. Neurofilaments comprise the axoskeleton and they functionally maintain the neuronal caliber. They may also play a role in intracellular transport to axons and dendrites. This gene encodes the light chain neurofilament protein. Mutations in this gene cause Charcot-Marie-Tooth disease types 1F (CMT1F) and 2E (CMT2E), disorders of the peripheral nervous system that are characterized by distinct neuropathies. A pseudogene has been identified on chromosome Y.

Gene names and symbols associated with NEFL

  • neurofilament light (NEFL)
  • neurofilament, light polypeptide (NEFL)
  • neurofilament, light polypeptide b (neflb)
  • neurofilament, light polypeptide (Nefl)
  • neurofilament light (Nefl)
  • neurofilament, light L homeolog (nefl.L)
  • AI847934 protein
  • CMT1F protein
  • CMT2E protein
  • nefl protein
  • NF-L protein
  • NF68 protein
  • NFL protein
  • XNF-L protein
  • zgc:136626 protein

Protein level used designations for NEFL

neurofilament, light polypeptide 68kDa , neurofilament, light polypeptide , neurofilament light polypeptide , 68 kDa neurofilament protein , neurofilament protein L , neurofilament triplet L protein , light molecular weight neurofilament protein , neurofilament protein, light chain , neurofilament subunit NF-L , NF-L , micro glutamic acid-rich protein , neurofilament protein , Neurofilament triplet L protein

GENE ID SPECIES
464063 Pan troglodytes
477378 Canis lupus familiaris
641444 Macaca mulatta
664698 Danio rerio
18039 Mus musculus
4747 Homo sapiens
83613 Rattus norvegicus
281348 Bos taurus
100521224 Sus scrofa
397822 Xenopus laevis
419528 Gallus gallus
100173482 Pongo abelii
Selected quality suppliers for Neurofilament, Light Polypeptide Proteins (NEFL)
Did you look for something else?